Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Memantine and Pioglitazone for Prevention of Radiation-Induced Brain Injury
NCT06594172Phase 2Not yet recruiting
- Sponsor
- Cancer Center of Guangzhou Medical University
- Start
- Sep 2024
- Primary completion
- Dec 2025
- Modality
- Small Molecules
01
Overview
A Phase 2 trial of memantine, pioglitazone in Radiation-Induced Brain Injury (RIBI), sponsored by Cancer Center of Guangzhou Medical University. Planned start Sep 2024; status: not yet recruiting.
02
Drugs
memantinepioglitazone
03
Conditions
Radiation-Induced Brain Injury (RIBI)
Beyond the preview
Go deeper on NCT06594172.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06594172.